Clinical trials: Myelitis
Transverse Myelitis
Study to Investigate the Safety of the Transplantation of Human Glial Restricted Progenitor Cells Into Subjects With Transverse Myelitis
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early activity of Q-Cells® transplantation in subjects…
- Trial name
- NCT03887273
- Testing
- Q-Cells
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Q Therapeutics, Inc.
Neurogenic Detrusor Overactivity
Open-label, Long-term Safety, Efficacy, and Pharmacokinetics Study of Vibegron in Pediatric Subjects 2 Years to < 18 Years of Age With NDO and on CIC
The purpose of this study is to evaluate the safety, efficacy, and PK of Vibegron in pediatric participants with NDO who are regularly using CIC
- Trial name
- KANGUROO (NCT05491525)
- Testing
- Vibegron
- Where
- 38 sites in United States, Belgium and 14 more
- Volunteers
- 71 people
- Sponsor
- Urovant Sciences GmbH
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD
The primary purpose of this study is to evaluate the efficacy and safety of ravulizumab for the treatment of adult participants with NMOSD.
- Trial name
- NCT04201262
- Testing
- Ravulizumab
- Where
- 41 sites in United States, Australia and 11 more
- Volunteers
- 58 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder
The objective of this study is to evaluate the safety and efficacy of eculizumab in pediatric participants (aged 2 to < 18 years) with relapsing neuromyelitis optica spectrum disorder (NMOSD).
- Trial name
- NCT04155424
- Testing
- Eculizumab
- Where
- 35 sites in United States, Canada and 5 more
- Volunteers
- 5 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO.
- Trial name
- NCT02003144
- Testing
- eculizumab
- Where
- 69 sites in United States, Argentina and 18 more
- Volunteers
- 119 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
West Nile Virus Infection
Expanded Access to MGAWN1 in Subjects With Suspected West Nile Neuroinvasive Disease; Suspected West Nile Virus Infection; or Substantial Accidental Exposure
This study will test an experimental drug called MGAWN1 for the treatment of West Nile infections.
- Trial name
- NCT01206504
- Testing
- MGAWN1
- Sponsor
- MacroGenics
West Nile Neuroinvasive Disease, West Nile Virus Infection
Treatment of West Nile Virus With MGAWN1
This study will test a drug called MGAWN1 for the treatment of West Nile infections.
- Conditions
- West Nile Neuroinvasive Disease, West Nile Virus Infection, Encephalitis, Meningitis
- Trial name
- PARADIGM (NCT00927953)
- Testing
- MGAWN1
- Volunteers
- 13 people
- Sponsor
- MacroGenics
Neuromyelitis Optica, Neuromyelitis Optica Spectrum Disorder
A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)
The objectives of this time-to-event study were to assess the efficacy and safety of eculizumab as compared with placebo in participants with neuromyelitis optica spectrum disorder (NMOSD) who were anti-aquaporin-4 (AQP4)…
- Trial name
- NCT01892345
- Testing
- Eculizumab
- Where
- 70 sites in United States, Argentina and 16 more
- Volunteers
- 143 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis
Central Pain Study for ABX-1431
This study will determine the safety and tolerability of ABX-1431 in patients with central pain when added on to background pain therapy.
- Conditions
- Neuromyelitis Optica Spectrum Disorder, Transverse Myelitis, Multiple Sclerosis, Longitudinally Extensive Transverse Myelitis
- Trial name
- NCT03138421
- Testing
- ABX-1431 HCl
- Where
- 2 sites in United Kingdom
- Volunteers
- 9 people
- Sponsor
- Abide Therapeutics
Multiple Sclerosis
Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis
The intent of this clinical study is to answer the questions: 1) is the proposed treatment safe and 2) is treatment effective in improving the disease pathology of patients with Multiple Sclerosis and clinical outcomes.
- Trial name
- NCT02326935
- Testing
- Autologous adipose derived mesenchymal cells
- Where
- Cayman Islands
- Volunteers
- 2 people
- Sponsor
- American CryoStem Corporation